Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2019-000607-33-ES
EUCTR2019-000607-33-ES
Active, not recruiting
Phase 1

A Phase II, randomized, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administered intramuscularly on a two-dose schedule to immunocompromised paediatric renal transplant recipients from 1 to 17 years of age. - ZOSTER-047

GlaxoSmithKline S.A.0 sites184 target enrollmentApril 30, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
GlaxoSmithKline S.A.
Enrollment
184
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 30, 2019
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Subjects’ parent(s)/Legally Acceptable Representative(s) \[LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
  • •Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure.
  • •Written informed assent obtained from the subjects when applicable according to local requirements.
  • •A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1\)
  • •Body weight \= 6 kg/13\.23 pounds.
  • •A subject is eligible if they meet at least one of the following criteria:
  • •\-Documented previous VZV vaccination OR
  • •\-Medically verified varicella OR
  • •\-Seropositive for VZV prior to transplantation.
  • •Subjects with renal transplant more than six months (180 days) prior randomization (Visit Day 1\)

Exclusion Criteria

  • •Medical conditions
  • •Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft
  • •Evidence of recurrent primary kidney disease within the current allograft
  • •Previous allograft loss secondary to recurrent primary kidney disease
  • •History of more than one organ transplanted
  • •Subjects with an episode of acute allograft rejection over the six months (180 days) prior to enrolment or receipt of treatment for rejection during the six months (180 days) prior to enrolment
  • •Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency (cRF) score that is unknown at the time of transplant
  • •VZV serostatus unknown prior to transplant
  • •Subjects with advanced chronic kidney disease
  • •Evidence of significant proteinuria

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A study to test GlaxoSmithKline’s (GSK) candidate vaccine-GSK1437173A for prevention of shingles in children with kidney transplantHerpes Zoster Renal transplant Pediatric populationTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2019-000607-33-FRGlaxoSmithKline Biologicals184
Active, not recruiting
Phase 1
A study to test GlaxoSmithKline’s (GSK) candidate vaccine-GSK1437173A for prevention of shingles in children with kidney transplant
EUCTR2019-000607-33-GBGlaxoSmithKline Biologicals184
Active, not recruiting
Not Applicable
A phase II, open-label, randomized, multicentre study to evaluate the feasibility of GSK Biologicals’ DTPa-IPV/Hib-MenC-TT vaccine co-administered with Prevenar compared with Pediacel co-administered with Menjugate and Prevenar, when given in healthy infants as a three-dose primary vaccination course at 2, 3 and 4 months of age and to evaluate Menitorix given to these children as a booster dose at 12 months of age - DTPA-IPV=HIB-MENC-TT-001 PRI
EUCTR2008-003741-87-GBGlaxoSmithKline Biologicals280
Active, not recruiting
Phase 1
A study to test GlaxoSmithKline's (GSK) candidate vaccine-GSK1437173A for prevention of shingles in children with kidney transplant.Herpes Zoster Renal transplant Pediatric populationMedDRA version: 20.1Level: LLTClassification code 10040555Term: ShinglesSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2019-000607-33-ITGLAXOSMITHKLINE BIOLOGICALS184
Active, not recruiting
Phase 1
A phase II, open-label, randomised, multicentre study to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals’ DTPa-HBV-IPV/Hib-MenC-TT vaccine, when given in healthy infants at 3, 5 and 11 months of age. - DTPA-HBV-IPV=HIB-MENC-TT-001 PRI
EUCTR2008-006365-91-SKGlaxoSmithKline Biologicals16